Related Experiment Video
Updated: Jul 15, 2025
Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
Published on: June 9, 2023
Potential of Dietary HDAC2i in Breast Cancer Patients Receiving PD-1/PD-L1 Inhibitors
Yuqian Wang1,2, Lingeng Lu3,4,5, Changquan Ling1,2
1Department of Chinese Medicine Oncology, The First Affiliated Hospital of Naval Medical University, Shanghai 200433, China.
Abstract:
Breast cancer (BC) is a lethal malignancy with high morbidity and mortality but lacks effective treatments thus far. Despite the introduction of immune checkpoint inhibitors (ICIs) (including PD-1/PD-L1 inhibitors), durable and optimal clinical benefits still remain elusive for a considerable number of BC patients. To break through such a dilemma, novel ICI-based combination therapy has been explored for enhancing the therapeutic effect. Recent evidence has just pointed out that the HDAC2 inhibitor (HDAC2i), which has been proven to exhibit an anti-cancer effect, can act as a sensitizer for ICIs therapy. Simultaneously, dietary intervention, as a crucial supportive therapy, has been reported to provide ingredients containing HDAC2 inhibitory activity. Thus, the novel integration of dietary intervention with ICIs therapy may offer promising possibilities for improving treatment outcomes. In this study, we first conducted the differential expression and prognostic analyses of HDAC2 and BC patients using the GENT2 and Kaplan-Meier plotter platform. Then, we summarized the potential diet candidates for such an integrated therapeutic strategy. This article not only provides a whole new therapeutic strategy for an HDAC2i-containing diet combined with PD-1/PD-L1 inhibitors for BC treatment, but also aims to ignite enthusiasm for exploring this field.
Insights
Combining dietary interventions with HDAC2 inhibitors and immune checkpoint inhibitors offers a new strategy for breast cancer treatment. This approach aims to improve patient outcomes where current therapies fall short.
Area of Science:
- Oncology
- Immunotherapy
- Nutritional Science
Background:
- Breast cancer (BC) remains a significant cause of mortality, with current treatments, including immune checkpoint inhibitors (ICIs), offering limited durable benefits for many patients.
- Histone deacetylase 2 inhibitor (HDAC2i) shows anti-cancer effects and can sensitize tumors to ICIs.
- Dietary interventions are recognized for their supportive role and can provide compounds with HDAC2 inhibitory activity.
Purpose of the Study:
- To explore the potential of integrating dietary interventions with HDAC2 inhibitors and ICIs for enhanced breast cancer treatment.
- To identify potential dietary candidates that can be incorporated into this novel therapeutic strategy.
Main Methods:
- Differential expression and prognostic analyses of HDAC2 in breast cancer patients were performed using the GENT2 and Kaplan-Meier plotter platforms.
- Literature review and summarization of potential dietary components with HDAC2 inhibitory activity.
Main Results:
- HDAC2 expression and prognostic correlations in breast cancer were analyzed.
- Potential dietary candidates with HDAC2 inhibitory properties were identified for integration into combination therapy.
Conclusions:
- A novel therapeutic strategy combining a diet rich in HDAC2 inhibitory compounds with PD-1/PD-L1 inhibitors presents a promising avenue for breast cancer treatment.
- This integrated approach has the potential to improve treatment efficacy and outcomes for breast cancer patients, particularly those unresponsive to current therapies.
Related Concept Videos
02:34Inhibition of Cdk Activity
02:59Cancer Prevention
Some...